Literature DB >> 16273793

The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis.

D Aletaha1, J Smolen.   

Abstract

Composite indices or pooled indices are useful tools for the evaluation of disease activity in patients with rheumatoid arthritis (RA). They allow the integration of various aspects of the disease into a single numerical value, and may therefore facilitate consistent patient care and improve patient compliance, which both can lead to improved outcomes. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI) are two new tools for the evaluation of disease activity in RA. They have been developed to provide physicians and patients with simple and more comprehensible instruments. Moreover, the CDAI is the only composite index that does not incorporate an acute phase response and can therefore be used to conduct a disease activity evaluation essentially anytime and anywhere. These two new tools have not been developed to replace currently available instruments such as the DAS28, but rather to provide options for different environments. The comparative construct, content, and discriminant validity of all three indices--the DAS28, the SDAI, and the CDAI--allow physicians to base their choice of instrument on their infrastructure and their needs, and all of them can also be used in clinical trials.

Entities:  

Mesh:

Year:  2005        PMID: 16273793

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  227 in total

1.  Validity and interpretability of the QuickDASH in the assessment of hand disability in rheumatoid arthritis.

Authors:  Fausto Salaffi; Marco Di Carlo; Marina Carotti; Sonia Farah
Journal:  Rheumatol Int       Date:  2018-12-03       Impact factor: 2.631

2.  Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study.

Authors:  Barbora Šumová; Lucie Andrés Cerezo; Lenka Szczuková; Lucie Nekvindová; Michal Uher; Hana Hulejová; Radka Moravcová; Mariam Grigorian; Karel Pavelka; Jiří Vencovský; Ladislav Šenolt; Jakub Závada
Journal:  Rheumatol Int       Date:  2018-11-03       Impact factor: 2.631

3.  Evaluation of an interferon gamma assay in the diagnosis of latent tuberculosis infection in patients with rheumatoid arthritis.

Authors:  Cláudia Diniz Lopes Marques; Ângela Luzia Branco Pinto Duarte; Virginia Maria Barros de Lorena; Joelma Rodrigues Souza; Wayner Vieira Souza; Yara de Miranda Gomes; Eduardo Maia Freese de Carvalho
Journal:  Rheumatol Int       Date:  2009-11       Impact factor: 2.631

4.  Clinical relevance of P-glycoprotein activity on peripheral blood mononuclear cells and polymorphonuclear neutrophils to methotrexate in systemic lupus erythematosus patients.

Authors:  Mario García-Carrasco; Claudia Mendoza-Pinto; Salvador Macías-Díaz; Ivet Etchegaray-Morales; Socorro Méndez-Martínez; Pamela Soto-Santillán; Beatriz Pérez-Romano; Erick A Jiménez-Herrera; Omar Guzmán-Ruiz; Alejandro Ruiz-Argüelles
Journal:  Clin Rheumatol       Date:  2017-06-14       Impact factor: 2.980

5.  Autoantibodies against a novel citrullinated fibrinogen peptide related to smoking status, disease activity and therapeutic response to methotrexate in cuban patients with early rheumatoid arthritis.

Authors:  Goitybell Martínez; Eugen Feist; Maité Martiatu; Hilda Garay; Bárbara Torres
Journal:  Rheumatol Int       Date:  2020-05-29       Impact factor: 2.631

6.  Pain-related comorbidities and medication absence as predictors of clinical remission in RA.

Authors:  D Vega-Morales; S A Loredo-Alanís; M A Garza-Elizondo
Journal:  Clin Rheumatol       Date:  2015-05-15       Impact factor: 2.980

7.  Patterns of circulatory and peripheral blood mononuclear cytokines in rheumatoid arthritis.

Authors:  Fawaz Y Azizieh; Khaled Al Jarallah; Diaa Shehab; Renu Gupta; Kamaludin Dingle; Raj Raghupathy
Journal:  Rheumatol Int       Date:  2017-07-19       Impact factor: 2.631

8.  Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort.

Authors:  Veena K Ranganath; Jeonglim Yoon; Dinesh Khanna; Grace S Park; Daniel E Furst; David A Elashoff; Damini Jawaheer; John T Sharp; Richard H Gold; Edward C Keystone; Harold E Paulus
Journal:  Ann Rheum Dis       Date:  2007-05-01       Impact factor: 19.103

9.  Cross-cultural adaptation and validation of the Thai version of the Rheumatoid Arthritis Disease Activity Index (RADAI).

Authors:  Wanruchada Katchamart; Prapassorn Ussavasodhi; Praveena Chiowchanwesawakit; Wanwisa Chanapai
Journal:  Rheumatol Int       Date:  2013-04-16       Impact factor: 2.631

Review 10.  Outcome measures in inflammatory rheumatic diseases.

Authors:  Jaap Fransen; Piet L C M van Riel
Journal:  Arthritis Res Ther       Date:  2009-10-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.